Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin‐associated weight gain: 52‐week results from the Effect of Liraglutide on insulin‐associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized controlled trial

• Published in: Journal of internal medicine 2016-03, Vol.279 (3), p.283-292
• Main Authors: Wit, H. M., Vervoort, G. M., Jansen, H. J., Galan, B. E., Tack, C. J.
• Format: Article
• Language: English
• Subjects: Diabetes Mellitus, Type 2 - drug therapy; Female; glucagon‐like peptide 1; Humans; Hypoglycemic Agents - therapeutic use; insulin; Insulin - adverse effects; Insulin - therapeutic use; liraglutide; Liraglutide - therapeutic use; Male; Middle Aged; Time Factors; Treatment Outcome; type 2 diabetes mellitus; weight gain; Weight Gain - drug effects
• ISSN: 0954-6820; 1365-2796
• DOI: 10.1111/joim.12447

Background Pronounced weight gain frequently complicates insulin therapy in patients with type 2 diabetes (T2DM). We have previously reported that addition of liraglutide for 26 weeks can reverse insulin‐associated weight gain, decrease insulin dose and improve glycaemic control, as compared with continuation of standard insulin treatment. Objectives To investigate whether the beneficial effects of liraglutide are sustained up to 52 weeks and whether similar effects could be obtained when liraglutide is added 6 months later. Methods Adult T2DM patients with ≥4% weight gain within 16 months of insulin therapy completing the first 26‐week trial period of open‐label addition of liraglutide 1.8 mg day−1 (n = 26) versus continuation of standard insulin therapy (n = 24) were all treated with liraglutide for another 26 weeks. Results were analysed according to the intention‐to‐treat principle. Results Overall, 24 (92%) and 18 (75%) patients originally assigned to liraglutide and standard therapy, respectively, completed the study. Addition of liraglutide decreased body weight to a similar extend when given in the first 26 weeks (liraglutide group) or second 26 weeks (original standard therapy group): −4.4 vs. −4.3 kg (difference −0.32 kg, 95% confidence interval −2.2 to 1.6 kg; P = 0.74). Similar results were also seen in the two groups with regard to decrease in haemoglobin A1c (HbA1c) (−0.77 vs. −0.66%; P = 0.23) and insulin dose (−28 vs. −26 U day−1; P = 0.32). In both groups, 22% of patients could discontinue insulin. Continuation of liraglutide until 52 weeks led to sustained effects on body weight, HbA1c and insulin‐dose requirements. Conclusion In T2DM patients with pronounced insulin‐associated weight gain, addition of liraglutide within 2 years leads to sustained reversal of body weight, improved glycaemic control and decrease in insulin dose. Thus, liraglutide offers a valuable therapeutic option.